Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 13/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7605670 | 0.83 | LTB4R2 (0.57) | LTB4R2AGTR1 | |
| SCHEMBL14132409 | 0.83 | LTB4R2 (0.49) | ALDH1A1LTB4R2AGTR1BCAT2SLC6A4 | |
| SCHEMBL27907961 | 0.83 | TAAR1 (0.47) | ALDH1A1ALOX15LTB4R2BCAT2SLC6A4 | |
| SCHEMBL7605043 | 0.80 | SLC6A3 (0.62) | ALDH1A1ALOX15LTB4R2BCAT2SLC6A4 | |
| SCHEMBL8692647 | 0.80 | PPARG (0.49) | LTB4R2AGTR1 | |
| SCHEMBL18825620 | 0.80 | BCAT2 (0.59) | ALDH1A1ALOX15BCAT2SLC6A4SLC6A3 | |
| SCHEMBL229441 | 0.79 | BCAT2 (0.63) | ALDH1A1ALOX15BCAT2SLC6A4SLC6A3 | |
| SCHEMBL8871967 | 0.79 | SLC6A3 (0.69) | LTB4R2AGTR1SLC6A4SLC6A3 | |
| SCHEMBL29697585 | 0.78 | BCAT2 (0.47) | ALDH1A1ALOX15LTB4R2BCAT2SLC6A4 | |
| SCHEMBL28640320 | 0.78 | SLC6A3 (0.64) | ALDH1A1ALOX15LTB4R2BCAT2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | ALDH1A1 190/4885ALOX15 589/4885LTB4R2 1837/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | ALDH1A1 603/4885ALOX15 560/4885LTB4R2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.